High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.

[1]  M. Carducci,et al.  Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. , 2015, European urology.

[2]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[4]  B. Trock,et al.  Obesity and long-term survival after radical prostatectomy. , 2014, The Journal of urology.

[5]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[6]  F. Jardin,et al.  Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy , 2014, European journal of haematology.

[7]  S. Heymsfield,et al.  Obesity paradox in cancer: new insights provided by body composition. , 2014, The American journal of clinical nutrition.

[8]  F. Jardin,et al.  Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2014, Leukemia & lymphoma.

[9]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Tunariu,et al.  Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer , 2013, British Journal of Cancer.

[11]  L. Mccargar,et al.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[13]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[14]  F. Saad,et al.  Sarcopenia during androgen-deprivation therapy for prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Douglas G. Altman,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[16]  T. Travison,et al.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. , 2012, Asian journal of andrology.

[17]  M. Dowsett,et al.  Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[18]  F. Wacker,et al.  Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? , 2011, The oncologist.

[19]  D. Bolton,et al.  Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy , 2011, Clinical endocrinology.

[20]  Y. Naya,et al.  Influence of Visceral Obesity on Oncologic Outcome in Patients with Renal Cell Carcinoma , 2010, Urologia Internationalis.

[21]  I. Tannock,et al.  Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[22]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[23]  T. Britton,et al.  Lipolysis—Not inflammation, cell death, or lipogenesis—Is involved in adipose tissue loss in cancer cachexia , 2008, Cancer.

[24]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[25]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[26]  C. Bing,et al.  Regulation of adipose tissue metabolism in cancer cachexia , 2008, Current opinion in clinical nutrition and metabolic care.

[27]  E. Small,et al.  Inverse correlation between body mass index and clinical outcomes in men with advanced castration–recurrent prostate cancer , 2007, Cancer.

[28]  S. Anker,et al.  Risk factor paradox in wasting diseases , 2007, Current opinion in clinical nutrition and metabolic care.

[29]  P. Arner,et al.  Mechanism of increased lipolysis in cancer cachexia. , 2007, Cancer research.

[30]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[31]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[32]  M. Thun,et al.  Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[34]  F. Ghiringhelli,et al.  Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. , 2011, The oncologist.